Loading…
Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus
Among fatty acid-binding proteins (FABPs), secreted forms of FABP4 and FABP5, which are expressed in adipocytes and macrophages, act as bioactive molecules. We investigated concentrations of FABP4 and FABP5 in patients with type 2 diabetes mellitus. As a sub-analysis study of the Randomized Evaluati...
Saved in:
Published in: | Frontiers in endocrinology (Lausanne) 2020-09, Vol.11, p.575557-575557 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83 |
---|---|
cites | cdi_FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83 |
container_end_page | 575557 |
container_issue | |
container_start_page | 575557 |
container_title | Frontiers in endocrinology (Lausanne) |
container_volume | 11 |
creator | Furuhashi, Masato Sakuma, Ichiro Morimoto, Takeshi Higashiura, Yukimura Sakai, Akiko Matsumoto, Megumi Sakuma, Mio Shimabukuro, Michio Nomiyama, Takashi Arasaki, Osamu Node, Koichi Ueda, Shinichiro |
description | Among fatty acid-binding proteins (FABPs), secreted forms of FABP4 and FABP5, which are expressed in adipocytes and macrophages, act as bioactive molecules. We investigated concentrations of FABP4 and FABP5 in patients with type 2 diabetes mellitus.
As a sub-analysis study of the Randomized Evaluation of Anagliptin vs. Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial, 256 patients (male/female: 146/110, age: 68 ± 10 years) with type 2 diabetes mellitus and dyslipidemia who were receiving statin therapy were recruited. Patients who had been treated with a thiazolidinedione were excluded.
Several drugs which may modulate FABP4 levels including statins, dipeptidyl peptidase-4 inhibitors and angiotensin II receptor blockers had been administered in 100, 81, and 51% of the recruited patients, respectively. The level of FABP4, but not that of FABP5, was significantly higher in females than in males. Multivariable linear regression analysis demonstrated that waist circumference (β = 0.21), estimated glomerular filtration rate (β = -0.31), triglycerides (β = 0.16), and FABP5 (β = 0.39) were independent predictors of FABP4 level after adjusting age and sex. On the other hand, FABP5 level was independently associated with levels of FABP4 (β = 0.57) and high-density lipoprotein (HDL) cholesterol (β = -0.12).
Concentrations of FABP4 and FABP5 are independent predictors of each other in patients with type 2 diabetes mellitus. There are distinct independent associations of FABP4 with renal dysfunction, adiposity and hypertriglyceridemia and there is a distinct independent association of FABP5 with a low HDL cholesterol level in type 2 diabetic patients with dyslipidemia at high risks for cardiovascular disease who are receiving statin therapy. |
doi_str_mv | 10.3389/fendo.2020.575557 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3f83f02886a94ad6981bbf23916451ba</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_3f83f02886a94ad6981bbf23916451ba</doaj_id><sourcerecordid>2452098248</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83</originalsourceid><addsrcrecordid>eNpVkU9PnCEQxklTU436AXppOPayK39f4NJkq7VuYqMHTY8EeEEx78IW2CZ--7K71igXJjPP_GYyDwCfMZpTKtVZ8GnMc4IImnPBORcfwBEeBjYjVJGPb-JDcFrrE-qPIayU_AQOKUUCK0mOQFqm0a87yqcGTRrhRawtJtfgotbsomkxpwpzgJeL77dsJ9lGHP6O7RH-8s3YPEUHb00xK998qTAmePe89pB0mLE9V7tummLb1BNwEMxU_enLfwzuL3_cnV_Nrm9-Ls8X1zPHBt5mRMggRkwsRkZI70QYveFCMKEwMz2W3AqpPFHcKkcsIlSgXqKD4tRZSY_Bcs8ds3nS6xJXpjzrbKLeJXJ50Ka06CavaZA0ICLlYFRnD0pia0M_HB4Yx9Z01rc9a72xKz-6fqlipnfQ95UUH_VD_qsFp5Kz7TJfXwAl_9n42vQqVtcvYpLPm6oJ4wR1N3ZSvJe6kmstPryOwUhvbdc72_XWdr23vfd8ebvfa8d_k-k_m26ojQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2452098248</pqid></control><display><type>article</type><title>Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus</title><source>Open Access: PubMed Central</source><creator>Furuhashi, Masato ; Sakuma, Ichiro ; Morimoto, Takeshi ; Higashiura, Yukimura ; Sakai, Akiko ; Matsumoto, Megumi ; Sakuma, Mio ; Shimabukuro, Michio ; Nomiyama, Takashi ; Arasaki, Osamu ; Node, Koichi ; Ueda, Shinichiro</creator><creatorcontrib>Furuhashi, Masato ; Sakuma, Ichiro ; Morimoto, Takeshi ; Higashiura, Yukimura ; Sakai, Akiko ; Matsumoto, Megumi ; Sakuma, Mio ; Shimabukuro, Michio ; Nomiyama, Takashi ; Arasaki, Osamu ; Node, Koichi ; Ueda, Shinichiro</creatorcontrib><description>Among fatty acid-binding proteins (FABPs), secreted forms of FABP4 and FABP5, which are expressed in adipocytes and macrophages, act as bioactive molecules. We investigated concentrations of FABP4 and FABP5 in patients with type 2 diabetes mellitus.
As a sub-analysis study of the Randomized Evaluation of Anagliptin vs. Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial, 256 patients (male/female: 146/110, age: 68 ± 10 years) with type 2 diabetes mellitus and dyslipidemia who were receiving statin therapy were recruited. Patients who had been treated with a thiazolidinedione were excluded.
Several drugs which may modulate FABP4 levels including statins, dipeptidyl peptidase-4 inhibitors and angiotensin II receptor blockers had been administered in 100, 81, and 51% of the recruited patients, respectively. The level of FABP4, but not that of FABP5, was significantly higher in females than in males. Multivariable linear regression analysis demonstrated that waist circumference (β = 0.21), estimated glomerular filtration rate (β = -0.31), triglycerides (β = 0.16), and FABP5 (β = 0.39) were independent predictors of FABP4 level after adjusting age and sex. On the other hand, FABP5 level was independently associated with levels of FABP4 (β = 0.57) and high-density lipoprotein (HDL) cholesterol (β = -0.12).
Concentrations of FABP4 and FABP5 are independent predictors of each other in patients with type 2 diabetes mellitus. There are distinct independent associations of FABP4 with renal dysfunction, adiposity and hypertriglyceridemia and there is a distinct independent association of FABP5 with a low HDL cholesterol level in type 2 diabetic patients with dyslipidemia at high risks for cardiovascular disease who are receiving statin therapy.</description><identifier>ISSN: 1664-2392</identifier><identifier>EISSN: 1664-2392</identifier><identifier>DOI: 10.3389/fendo.2020.575557</identifier><identifier>PMID: 33071982</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>adipokine ; diabetes mellitus ; dipeptidyl peptidase-4 inhibitor ; Endocrinology ; fatty acid-binding protein ; stain</subject><ispartof>Frontiers in endocrinology (Lausanne), 2020-09, Vol.11, p.575557-575557</ispartof><rights>Copyright © 2020 Furuhashi, Sakuma, Morimoto, Higashiura, Sakai, Matsumoto, Sakuma, Shimabukuro, Nomiyama, Arasaki, Node and Ueda.</rights><rights>Copyright © 2020 Furuhashi, Sakuma, Morimoto, Higashiura, Sakai, Matsumoto, Sakuma, Shimabukuro, Nomiyama, Arasaki, Node and Ueda. 2020 Furuhashi, Sakuma, Morimoto, Higashiura, Sakai, Matsumoto, Sakuma, Shimabukuro, Nomiyama, Arasaki, Node and Ueda</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83</citedby><cites>FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538548/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538548/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33071982$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Furuhashi, Masato</creatorcontrib><creatorcontrib>Sakuma, Ichiro</creatorcontrib><creatorcontrib>Morimoto, Takeshi</creatorcontrib><creatorcontrib>Higashiura, Yukimura</creatorcontrib><creatorcontrib>Sakai, Akiko</creatorcontrib><creatorcontrib>Matsumoto, Megumi</creatorcontrib><creatorcontrib>Sakuma, Mio</creatorcontrib><creatorcontrib>Shimabukuro, Michio</creatorcontrib><creatorcontrib>Nomiyama, Takashi</creatorcontrib><creatorcontrib>Arasaki, Osamu</creatorcontrib><creatorcontrib>Node, Koichi</creatorcontrib><creatorcontrib>Ueda, Shinichiro</creatorcontrib><title>Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus</title><title>Frontiers in endocrinology (Lausanne)</title><addtitle>Front Endocrinol (Lausanne)</addtitle><description>Among fatty acid-binding proteins (FABPs), secreted forms of FABP4 and FABP5, which are expressed in adipocytes and macrophages, act as bioactive molecules. We investigated concentrations of FABP4 and FABP5 in patients with type 2 diabetes mellitus.
As a sub-analysis study of the Randomized Evaluation of Anagliptin vs. Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial, 256 patients (male/female: 146/110, age: 68 ± 10 years) with type 2 diabetes mellitus and dyslipidemia who were receiving statin therapy were recruited. Patients who had been treated with a thiazolidinedione were excluded.
Several drugs which may modulate FABP4 levels including statins, dipeptidyl peptidase-4 inhibitors and angiotensin II receptor blockers had been administered in 100, 81, and 51% of the recruited patients, respectively. The level of FABP4, but not that of FABP5, was significantly higher in females than in males. Multivariable linear regression analysis demonstrated that waist circumference (β = 0.21), estimated glomerular filtration rate (β = -0.31), triglycerides (β = 0.16), and FABP5 (β = 0.39) were independent predictors of FABP4 level after adjusting age and sex. On the other hand, FABP5 level was independently associated with levels of FABP4 (β = 0.57) and high-density lipoprotein (HDL) cholesterol (β = -0.12).
Concentrations of FABP4 and FABP5 are independent predictors of each other in patients with type 2 diabetes mellitus. There are distinct independent associations of FABP4 with renal dysfunction, adiposity and hypertriglyceridemia and there is a distinct independent association of FABP5 with a low HDL cholesterol level in type 2 diabetic patients with dyslipidemia at high risks for cardiovascular disease who are receiving statin therapy.</description><subject>adipokine</subject><subject>diabetes mellitus</subject><subject>dipeptidyl peptidase-4 inhibitor</subject><subject>Endocrinology</subject><subject>fatty acid-binding protein</subject><subject>stain</subject><issn>1664-2392</issn><issn>1664-2392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU9PnCEQxklTU436AXppOPayK39f4NJkq7VuYqMHTY8EeEEx78IW2CZ--7K71igXJjPP_GYyDwCfMZpTKtVZ8GnMc4IImnPBORcfwBEeBjYjVJGPb-JDcFrrE-qPIayU_AQOKUUCK0mOQFqm0a87yqcGTRrhRawtJtfgotbsomkxpwpzgJeL77dsJ9lGHP6O7RH-8s3YPEUHb00xK998qTAmePe89pB0mLE9V7tummLb1BNwEMxU_enLfwzuL3_cnV_Nrm9-Ls8X1zPHBt5mRMggRkwsRkZI70QYveFCMKEwMz2W3AqpPFHcKkcsIlSgXqKD4tRZSY_Bcs8ds3nS6xJXpjzrbKLeJXJ50Ka06CavaZA0ICLlYFRnD0pia0M_HB4Yx9Z01rc9a72xKz-6fqlipnfQ95UUH_VD_qsFp5Kz7TJfXwAl_9n42vQqVtcvYpLPm6oJ4wR1N3ZSvJe6kmstPryOwUhvbdc72_XWdr23vfd8ebvfa8d_k-k_m26ojQ</recordid><startdate>20200923</startdate><enddate>20200923</enddate><creator>Furuhashi, Masato</creator><creator>Sakuma, Ichiro</creator><creator>Morimoto, Takeshi</creator><creator>Higashiura, Yukimura</creator><creator>Sakai, Akiko</creator><creator>Matsumoto, Megumi</creator><creator>Sakuma, Mio</creator><creator>Shimabukuro, Michio</creator><creator>Nomiyama, Takashi</creator><creator>Arasaki, Osamu</creator><creator>Node, Koichi</creator><creator>Ueda, Shinichiro</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200923</creationdate><title>Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus</title><author>Furuhashi, Masato ; Sakuma, Ichiro ; Morimoto, Takeshi ; Higashiura, Yukimura ; Sakai, Akiko ; Matsumoto, Megumi ; Sakuma, Mio ; Shimabukuro, Michio ; Nomiyama, Takashi ; Arasaki, Osamu ; Node, Koichi ; Ueda, Shinichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>adipokine</topic><topic>diabetes mellitus</topic><topic>dipeptidyl peptidase-4 inhibitor</topic><topic>Endocrinology</topic><topic>fatty acid-binding protein</topic><topic>stain</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Furuhashi, Masato</creatorcontrib><creatorcontrib>Sakuma, Ichiro</creatorcontrib><creatorcontrib>Morimoto, Takeshi</creatorcontrib><creatorcontrib>Higashiura, Yukimura</creatorcontrib><creatorcontrib>Sakai, Akiko</creatorcontrib><creatorcontrib>Matsumoto, Megumi</creatorcontrib><creatorcontrib>Sakuma, Mio</creatorcontrib><creatorcontrib>Shimabukuro, Michio</creatorcontrib><creatorcontrib>Nomiyama, Takashi</creatorcontrib><creatorcontrib>Arasaki, Osamu</creatorcontrib><creatorcontrib>Node, Koichi</creatorcontrib><creatorcontrib>Ueda, Shinichiro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in endocrinology (Lausanne)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Furuhashi, Masato</au><au>Sakuma, Ichiro</au><au>Morimoto, Takeshi</au><au>Higashiura, Yukimura</au><au>Sakai, Akiko</au><au>Matsumoto, Megumi</au><au>Sakuma, Mio</au><au>Shimabukuro, Michio</au><au>Nomiyama, Takashi</au><au>Arasaki, Osamu</au><au>Node, Koichi</au><au>Ueda, Shinichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus</atitle><jtitle>Frontiers in endocrinology (Lausanne)</jtitle><addtitle>Front Endocrinol (Lausanne)</addtitle><date>2020-09-23</date><risdate>2020</risdate><volume>11</volume><spage>575557</spage><epage>575557</epage><pages>575557-575557</pages><issn>1664-2392</issn><eissn>1664-2392</eissn><abstract>Among fatty acid-binding proteins (FABPs), secreted forms of FABP4 and FABP5, which are expressed in adipocytes and macrophages, act as bioactive molecules. We investigated concentrations of FABP4 and FABP5 in patients with type 2 diabetes mellitus.
As a sub-analysis study of the Randomized Evaluation of Anagliptin vs. Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial, 256 patients (male/female: 146/110, age: 68 ± 10 years) with type 2 diabetes mellitus and dyslipidemia who were receiving statin therapy were recruited. Patients who had been treated with a thiazolidinedione were excluded.
Several drugs which may modulate FABP4 levels including statins, dipeptidyl peptidase-4 inhibitors and angiotensin II receptor blockers had been administered in 100, 81, and 51% of the recruited patients, respectively. The level of FABP4, but not that of FABP5, was significantly higher in females than in males. Multivariable linear regression analysis demonstrated that waist circumference (β = 0.21), estimated glomerular filtration rate (β = -0.31), triglycerides (β = 0.16), and FABP5 (β = 0.39) were independent predictors of FABP4 level after adjusting age and sex. On the other hand, FABP5 level was independently associated with levels of FABP4 (β = 0.57) and high-density lipoprotein (HDL) cholesterol (β = -0.12).
Concentrations of FABP4 and FABP5 are independent predictors of each other in patients with type 2 diabetes mellitus. There are distinct independent associations of FABP4 with renal dysfunction, adiposity and hypertriglyceridemia and there is a distinct independent association of FABP5 with a low HDL cholesterol level in type 2 diabetic patients with dyslipidemia at high risks for cardiovascular disease who are receiving statin therapy.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>33071982</pmid><doi>10.3389/fendo.2020.575557</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1664-2392 |
ispartof | Frontiers in endocrinology (Lausanne), 2020-09, Vol.11, p.575557-575557 |
issn | 1664-2392 1664-2392 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_3f83f02886a94ad6981bbf23916451ba |
source | Open Access: PubMed Central |
subjects | adipokine diabetes mellitus dipeptidyl peptidase-4 inhibitor Endocrinology fatty acid-binding protein stain |
title | Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T04%3A31%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Independent%20and%20Distinct%20Associations%20of%20FABP4%20and%20FABP5%20With%20Metabolic%20Parameters%20in%20Type%202%20Diabetes%20Mellitus&rft.jtitle=Frontiers%20in%20endocrinology%20(Lausanne)&rft.au=Furuhashi,%20Masato&rft.date=2020-09-23&rft.volume=11&rft.spage=575557&rft.epage=575557&rft.pages=575557-575557&rft.issn=1664-2392&rft.eissn=1664-2392&rft_id=info:doi/10.3389/fendo.2020.575557&rft_dat=%3Cproquest_doaj_%3E2452098248%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-278f7d12b10a78ec7fdea57747914adea85b789e295b9c2b0237091436953cb83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2452098248&rft_id=info:pmid/33071982&rfr_iscdi=true |